{"id":15389,"date":"2022-02-09T00:00:00","date_gmt":"2022-02-09T00:00:00","guid":{"rendered":"https:\/\/cms.alj3.clients.lemonhq.io\/perspectives\/healthcare-for-the-many-not-only-the-few-6\/"},"modified":"2026-05-12T14:17:49","modified_gmt":"2026-05-12T14:17:49","slug":"healthcare-for-the-many-not-only-the-few-6","status":"publish","type":"perspectives","link":"https:\/\/cms.alj3.clients.lemonhq.io\/es\/perspectives\/healthcare-for-the-many-not-only-the-few-6\/","title":{"rendered":"Atenci\u00f3n sanitaria para muchos, no solo para unos pocos"},"content":{"rendered":"<h4>A Q&amp;A with Melanie Nallicheri, CEO of EQRx, on a mission to remake medicine.<\/h4>\n<p>In June 2021, <a href=\"https:\/\/aljhealth.com\/home\">Abdul Latif Jameel Health<\/a> and <a href=\"http:\/\/www.eqrx.com\">EQRx<\/a>, a company committed to developing and delivering break-through medicines at lower prices, signed a strategic collaboration for the distribution of two affordable new lung cancer drugs \u2013 once these have been fully approved by all relevant authorities &#8211; to a potential 1.5 billion people across the Middle East, Africa and Turkey.<\/p>\n<p>The two oncology programs, aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor and sugemalimab, an anti-PD-L1 antibody, have shown promising Phase 3 data for the treatment of patients with advanced non-small cell lung cancer (NSCLC).\u00a0 \u00a0These therapies have the potential to offer treatment at a fraction of the cost of existing approaches.<\/p>\n<p>This collaboration will see Abdul Latif Jameel Health commercialize the drugs to selected markets throughout the Middle East region, as well as in Turkey and all of Africa, providing access to affordable, safe, effective treatment for thousands of lung cancer patients.<\/p>\n<p>We spoke to <a href=\"https:\/\/www.eqrx.com\/people\/melanie-nallicheri\/\">Melanie Nallicheri<\/a>, Chief Executive Officer, EQRx, and <a href=\"https:\/\/aljhealth.com\/en\/our-people\/akram-bouchenaki\/\">Akram Bouchenaki<\/a>, CEO, Abdul Latif Jameel Health, about the partnership and what it could mean for cancer patients in the target markets.<\/p>\n<h2>Melanie, can you tell us about your mission at EQRx?<\/h2>\n<div id=\"attachment_95745\" style=\"width: 231px\" class=\"wp-caption alignright\"><img loading=\"lazy\" decoding=\"async\" aria-describedby=\"caption-attachment-95745\" class=\"size-medium wp-image-95745\" src=\"https:\/\/alj.com\/app\/uploads\/2022\/02\/Mellanie-Nalicheri-CEO-EQRx-221x300.jpg\" alt=\"Mellanie Nalicheri, CEO, EQRx\" width=\"221\" height=\"300\" \/><p id=\"caption-attachment-95745\" class=\"wp-caption-text\">Melanie Nallicheri,<br \/>CEO, EQRx<\/p><\/div>\n<p><strong>MN: <\/strong>Our mission is to improve health for all through great innovative, affordable medicines:<\/p>\n<ul>\n<li>so that people around the world can access these medicines for chronic or life-threatening diseases or conditions without any barriers;<\/li>\n<li>so prescribers around the world can offer them to their patients without unnecessary administrative challenges; and,<\/li>\n<li>so payers and health systems around the world can make these medicines available to patients in a financially sustainable way.<\/li>\n<\/ul>\n<p>What we are basically saying is, we want to make innovative, life-enhancing medicines available and accessible to patients all over the world.<\/p>\n<h2>Why are the issues of accessibility and affordability such big problems in the pharmaceutical industry?<\/h2>\n<p><strong>MN: <\/strong>Our understanding of medicine, biology and data science has developed enormously in recent years. \u00a0Things we can do today would have been seen as science fiction a decade or two ago. \u00a0What usually happens\u00a0 as technology moves forward, costs \u2013 or at least consumer prices \u2013 come down. \u00a0But in healthcare, costs have actually gone up. \u00a0This means our understanding and our capabilities have increased, but the accessibility and affordability of these new solutions has decreased. \u00a0We could see this was wrong, and we saw an opportunity to do things differently by building a successful business at scale to change this dynamic.<\/p>\n<div id=\"attachment_95752\" style=\"width: 283px\" class=\"wp-caption alignright\"><img loading=\"lazy\" decoding=\"async\" aria-describedby=\"caption-attachment-95752\" class=\"size-medium wp-image-95752\" src=\"https:\/\/alj.com\/app\/uploads\/2022\/02\/Dr.-Akram-Bouchenaki-CEO-Abdul-Latif-Jameel-Health-273x300.jpg\" alt=\"Dr. Akram Bouchenaki, CEO, Abdul Latif Jameel Health\" width=\"273\" height=\"300\" \/><p id=\"caption-attachment-95752\" class=\"wp-caption-text\">Dr. Akram Bouchenaki,<br \/>CEO, Abdul Latif Jameel Health<\/p><\/div>\n<p><strong>AB: <\/strong>To add to Melanie\u2019s point, there is an incredible unmet medical need for these drugs.\u00a0 If you look at the Gulf region, which generally has a good level of healthcare, lung cancer is the second most common cancer in men, and it is the leading cause of death by cancer in men.\u00a0 Up to 80 percent of cases are diagnosed at advanced stages, and the five-year survival is as low as 10 to 20 percent.<\/p>\n<p>This is why it is absolutely critical to massively expand access to these therapies.\u00a0 That\u2019s the vision that we\u2019re trying to implement.<\/p>\n<h2>This isn\u2019t a new problem, so what is different about EQRx\u2019s approach to addressing it?<\/h2>\n<p><strong>MN: <\/strong>We recognized that to make a real difference, you need a significant portfolio, or catalog, of medicines. \u00a0This allows you to offer many choices for treating chronic or life-threatening diseases and enables you to make the greatest impact. \u00a0Instead of starting with one or two drugs, we wanted to start with 10, 20, 30, focusing on critical areas like oncology and immune-inflammatory diseases.<\/p>\n<p>We are also coming at the problem from a different perspective, from the basis of a shared objective with prescribers and payers. \u00a0Normally a manufacturer will launch a great new drug, but they keep the price high to maximize their profits and keep their shareholders happy. \u00a0Prescribers want to offer this drug to their patients, while payers \u2013 like health insurers or national health schemes \u2013 want to make it available to their members and communities. \u00a0The problem is, the cost is so high they can only afford to prescribe to a certain number of people, otherwise it would blow their budget. \u00a0This means they have to restrict who can benefit from these drugs.\u00a0 In effect, the objectives of the manufacturers, the prescribers\/payers and the patients are at odds with each other.<\/p>\n<p>Our approach is to work towards a <em>shared objective<\/em> of making these medicines as widely available as possible. \u00a0To do this, we intend to make our pricing\u00a0 transparent, simple and radically lower. \u00a0We will benefit from selling more of our medicines, prescribers and payers benefit from offering these treatments to more people without breaking their budgets, and patients benefit from having access to life-enhancing healthcare.<\/p>\n<h2>How big a difference could this make for health systems as well as for patients?<\/h2>\n<p><strong>MN: <\/strong>The potential benefits are enormous.\u00a0 Our mission is to offer life-changing medicines at radically lower prices.\u00a0 By radically lower, we\u2019re talking a quarter, a third, a half lower.\u00a0 That makes a significant difference.\u00a0 For example, say there is a total global spend for a specific drug of US$ 10 billion, which isn\u2019t inconceivable for many immune-inflammatory diseases.\u00a0 Our drug might be priced at a third of the price of the current drug, so in a market of US$ 10 billion, there is immediately a potential saving of over US$ 6.6 billion.\u00a0 Of course, we\u2019re never going to own 100% of a market, but even if we only had 15% of the market \u2013 US$ 1.5 billion \u2013 by offering our drug at one-third of the price, that\u2019s still US$500 million in revenue for us and a saving of US$ 1 billion for the health system.\u00a0 So you can see how we can potentially build a great business yet also generate significant value for all of the other stakeholders in our ecosystem, not least the patients, who will have access to treatments that may have been previously unavailable to them.<\/p>\n<div id=\"attachment_95724\" style=\"width: 2277px\" class=\"wp-caption aligncenter\"><img loading=\"lazy\" decoding=\"async\" aria-describedby=\"caption-attachment-95724\" class=\"size-full wp-image-95724\" src=\"https:\/\/alj.com\/app\/uploads\/2022\/02\/Alexis-Borisy-Executive-Chairman-Board-of-Directors-Melanie-Nallicheri-Chief-Executive-Officer-EQRx.jpg\" alt=\"\" width=\"2267\" height=\"1074\" \/><p id=\"caption-attachment-95724\" class=\"wp-caption-text\">Pictured (L-R) Alexis Borisy, Executive Chairman, Board of Directors &amp; Melanie Nallicheri, Chief Executive Officer EQRx<br \/>Photo credit \u00a9 Fierce Biotech.<\/p><\/div>\n<h2>How has EQRx been able to overcome the barriers that have stopped someone doing this before?<\/h2>\n<p><strong>MN: <\/strong>There are three core pillars in our business model that we believe will enable us to do this. \u00a0The first is that, right from day one, we have had a laser-sharp focus on creating a completely different cost structure.\u00a0 We are a new business, so we\u2019ve been able to create that structure from the ground up right across the organization.\u00a0 Second, we are creating operational processes that leverage everything we have at our disposal as an industry to lower the cost of developing the medicine. \u00a0For instance, you can use remote approaches to monitor patients during a clinical trial, which means you can conduct trials much faster and more efficiently, which reduces costs.\u00a0 Lastly, because of this unique business model, we don\u2019t need the typical salesforce-driven, high-promotion approach to selling drugs.\u00a0 Our partners should be creating the pull-through and the access to our medicines, as opposed to us sending hundreds of salespeople to persuade people to buy them.\u00a0 This kind of market-driven model has not existed before in the global healthcare sector.<\/p>\n<h2>Akram, what was it about EQRx that convinced you they would be good partners for Abdul Latif Jameel Health?<\/h2>\n<p><strong>AB<\/strong>: As we were looking to become an investor in EQRx, we found a great alignment with the vision, the values and the overall purpose of EQRx. \u00a0Abdul Latif Jameel Health aims to be a bridge to accelerate access to innovative therapies in the global south. \u00a0\u00a0The two key words there are \u2018accelerate&#8217; and \u2018access\u2019.\u00a0 We want to get vital medicines \u00a0to people faster and make them accessible to more people.\u00a0 Affordability is a key part of that, but price is not the only factor preventing medicines reaching those who need them.\u00a0 I\u2019ve been in situations in my career where we have donated tons of drugs to treat infectious disease to countries where prevalence rates were very high, but unfortunately the drugs never made it to the patients who needed them. \u00a0So, there is more than just an affordability issue to address.<\/p>\n<p>The other thing we really liked with the EQRx approach is that we saw a great alignment with the innovative business model they are building, the way they\u2019re focusing on the right stakeholders for the future. \u00a0It is a vision and a strategy that we very much support and look forward to implementing in our part of the world.<\/p>\n<h2>Melanie, your first two products are both cancer drugs &#8211; aumolertinib and sugemalimab. Why did you choose to start with these two?<\/h2>\n<p><strong>MN: <\/strong>When we first started, we said we wanted to have our first drug available to patients within five years.\u00a0 That was part of our thinking when we were scanning the market for medicines to bring into our portfolio.\u00a0 Both aumolertinib and sugemalimab are for non-small-cell lung cancer, as well as other cancers.\u00a0 Aumolertinib is a targeted therapy in oncology for patients with EFGR-driven mutations.\u00a0 Sugemalimab is an immunotherapy. \u00a0In cancer, it\u2019s the largest drug class that we know today.<\/p>\n<p>We were very excited about these drugs, both of which have been shown to have excellent efficacy and a strong tolerability profile.<\/p>\n<p>Not only that, these two medicines could be available as early as 2023, which is much sooner than our original five-year target.\u00a0 This means we can start having conversations with regulatory agencies around the world, and with our partners around the world, to start the process of getting these drugs to the people that need them.\u00a0 It\u2019s the ideal scenario: a great medicine with a great tolerability profile, much sooner than we had originally anticipated. \u00a0That\u2019s why we were so excited about these two therapeutics.<\/p>\n<h2>Akram, how do you plan to leverage Abul Latif Jameel\u2019s global footprint to get these drugs to those who need them?<\/h2>\n<p><strong>AB:<\/strong> \u00a0This is the kind of challenge for which Abdul Latif Jameel Health was designed.\u00a0 It was the vision of <a href=\"https:\/\/alj.com\/en\/our-people\/mohammed-abdul-latif-jameel\/\">Mohammed Jameel<\/a> that we become a critical part of the innovation chain, because innovation is not just what happens in the lab.\u00a0 That\u2019s the starting point, of course, but innovation is also about finding new ways, faster and more effective ways, to deliver those therapies to patients.\u00a0 We see ourselves as the deliverers of that promise of innovation.\u00a0 These drugs are going to be absolutely central in transforming patient care, in prolonging life, in making cancer treatment better tolerated.\u00a0 The promise is there, and we see delivery as an integral part of that innovation journey.<\/p>\n<h2>What do you see as the biggest challenges for EQRx in achieving your ambitions?<\/h2>\n<p><strong>MN<\/strong>: \u00a0Our first challenge is to develop our catalogue of medicines and build up our organization at scale.\u00a0 To do that you need to be able to do two things. \u00a0One, you need to attract some of the best talent in the entire industry. \u00a0Two, you need to be able to mobilize significant capital to build an enterprise rapidly at scale. \u00a0We\u2019ve been working really diligently from the get-go on both. \u00a0On the people front, we have established a talent brand that\u2019s really unique, both because of our social mission, which is really exciting to people, and also because of the culture at EQRx that rewards enterprise and innovation. \u00a0People are encouraged and empowered to try to do things differently, even if we know that some of the ideas might not work.<\/p>\n<p><strong>AB: \u00a0<\/strong>For us, the challenge is to implement this uniquely innovative and disruptive model.\u00a0 We need to go out and change people\u2019s perceptions about how the drug market works.\u00a0 We don\u2019t want to have armies of sales reps hovering around corridors in hospitals, which is a huge waste of productive time, but rather focus on service, education, distribution.\u00a0 Partnering with healthcare authorities, regulators, and healthcare providers in general is going to be a key success factor for us as we build a new model of medicine where patients are actors in their own health.<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"size-full wp-image-95731 aligncenter\" src=\"https:\/\/alj.com\/app\/uploads\/2022\/02\/ALJ-Health.jpg\" alt=\"\" width=\"1516\" height=\"703\" \/><\/p>\n<h2>Finally, what\u2019s next for you both?<\/h2>\n<p><strong>MN:<\/strong> \u00a0We\u2019ll be focusing on building our catalogue and our organization.\u00a0 We have over 10 programs in our portfolio right now. \u00a0Of these, five are clinical-stage programs, including aumolertinib and sugemalimab.\u00a0 We also have another immunotherapy option in our portfolio. \u00a0We have a breast cancer drug, and we have a drug for major immuno-inflammatory diseases, like rheumatoid arthritis and atopic dermatitis. \u00a0After those, we have several earlier-stage programs that we\u2019re developing. \u00a0These include both oncology and immuno-inflammatory diseases, and then most recently, we\u2019ve announced several drug engineering collaborations with companies.\u00a0 By 2025 or 2026, we expect to be addressing more than 20% of the spend of a trillion-dollar global branded drug market. \u00a0And that\u2019s a hugely exciting prospect.<\/p>\n<p><strong>AB<\/strong>: \u00a0We can\u2019t wait to be part of that journey.\u00a0 We\u2019re looking forward to working with Melanie and the team at EQRx and really starting to put our strategy into practice.\u00a0 That\u2019s when the work really starts.\u00a0 We\u2019re super-excited. \u00a0We would love to see patients get access to these exciting new drugs as soon as we possibly can, and we\u2019ll do all we can to achieve that over the next few years, and hopefully beyond.<\/p>\n","protected":false},"featured_media":15377,"menu_order":0,"template":"","class_list":["post-15389","perspectives","type-perspectives","status-publish","has-post-thumbnail","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.5 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Atenci\u00f3n sanitaria para muchos, no solo para unos pocos - Abdul Latif Jameel<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Atenci\u00f3n sanitaria para muchos, no solo para unos pocos - Abdul Latif Jameel\" \/>\n<meta property=\"og:description\" content=\"A Q&amp;A with Melanie Nallicheri, CEO of EQRx, on a mission to remake medicine. In June 2021, Abdul Latif Jameel Health and EQRx, a company committed to developing and delivering break-through medicines at lower prices, signed a strategic collaboration for the distribution of two affordable new lung cancer drugs \u2013 once these have been fully [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cms.alj3.clients.lemonhq.io\/es\/perspectives\/healthcare-for-the-many-not-only-the-few-6\/\" \/>\n<meta property=\"og:site_name\" content=\"Abdul Latif Jameel\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-12T14:17:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/media.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/Cost-of-Drugs.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1511\" \/>\n\t<meta property=\"og:image:height\" content=\"868\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"11 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cms.alj3.clients.lemonhq.io\/es\/perspectives\/healthcare-for-the-many-not-only-the-few-6\/\",\"url\":\"https:\/\/cms.alj3.clients.lemonhq.io\/es\/perspectives\/healthcare-for-the-many-not-only-the-few-6\/\",\"name\":\"Atenci\u00f3n sanitaria para muchos, no solo para unos pocos - Abdul Latif Jameel\",\"isPartOf\":{\"@id\":\"https:\/\/10.0.2.222\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cms.alj3.clients.lemonhq.io\/es\/perspectives\/healthcare-for-the-many-not-only-the-few-6\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cms.alj3.clients.lemonhq.io\/es\/perspectives\/healthcare-for-the-many-not-only-the-few-6\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/media.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/Cost-of-Drugs.jpg\",\"datePublished\":\"2022-02-09T00:00:00+00:00\",\"dateModified\":\"2026-05-12T14:17:49+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cms.alj3.clients.lemonhq.io\/es\/perspectives\/healthcare-for-the-many-not-only-the-few-6\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cms.alj3.clients.lemonhq.io\/es\/perspectives\/healthcare-for-the-many-not-only-the-few-6\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/cms.alj3.clients.lemonhq.io\/es\/perspectives\/healthcare-for-the-many-not-only-the-few-6\/#primaryimage\",\"url\":\"https:\/\/media.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/Cost-of-Drugs.jpg\",\"contentUrl\":\"https:\/\/media.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/Cost-of-Drugs.jpg\",\"width\":1511,\"height\":868},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cms.alj3.clients.lemonhq.io\/es\/perspectives\/healthcare-for-the-many-not-only-the-few-6\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/10.0.2.222\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Atenci\u00f3n sanitaria para muchos, no solo para unos pocos\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/10.0.2.222\/en\/#website\",\"url\":\"https:\/\/10.0.2.222\/en\/\",\"name\":\"Abdul Latif Jameel\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/10.0.2.222\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Atenci\u00f3n sanitaria para muchos, no solo para unos pocos - Abdul Latif Jameel","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"es_ES","og_type":"article","og_title":"Atenci\u00f3n sanitaria para muchos, no solo para unos pocos - Abdul Latif Jameel","og_description":"A Q&amp;A with Melanie Nallicheri, CEO of EQRx, on a mission to remake medicine. In June 2021, Abdul Latif Jameel Health and EQRx, a company committed to developing and delivering break-through medicines at lower prices, signed a strategic collaboration for the distribution of two affordable new lung cancer drugs \u2013 once these have been fully [&hellip;]","og_url":"https:\/\/cms.alj3.clients.lemonhq.io\/es\/perspectives\/healthcare-for-the-many-not-only-the-few-6\/","og_site_name":"Abdul Latif Jameel","article_modified_time":"2026-05-12T14:17:49+00:00","og_image":[{"width":1511,"height":868,"url":"https:\/\/media.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/Cost-of-Drugs.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Tiempo de lectura":"11 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/cms.alj3.clients.lemonhq.io\/es\/perspectives\/healthcare-for-the-many-not-only-the-few-6\/","url":"https:\/\/cms.alj3.clients.lemonhq.io\/es\/perspectives\/healthcare-for-the-many-not-only-the-few-6\/","name":"Atenci\u00f3n sanitaria para muchos, no solo para unos pocos - Abdul Latif Jameel","isPartOf":{"@id":"https:\/\/10.0.2.222\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cms.alj3.clients.lemonhq.io\/es\/perspectives\/healthcare-for-the-many-not-only-the-few-6\/#primaryimage"},"image":{"@id":"https:\/\/cms.alj3.clients.lemonhq.io\/es\/perspectives\/healthcare-for-the-many-not-only-the-few-6\/#primaryimage"},"thumbnailUrl":"https:\/\/media.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/Cost-of-Drugs.jpg","datePublished":"2022-02-09T00:00:00+00:00","dateModified":"2026-05-12T14:17:49+00:00","breadcrumb":{"@id":"https:\/\/cms.alj3.clients.lemonhq.io\/es\/perspectives\/healthcare-for-the-many-not-only-the-few-6\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cms.alj3.clients.lemonhq.io\/es\/perspectives\/healthcare-for-the-many-not-only-the-few-6\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/cms.alj3.clients.lemonhq.io\/es\/perspectives\/healthcare-for-the-many-not-only-the-few-6\/#primaryimage","url":"https:\/\/media.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/Cost-of-Drugs.jpg","contentUrl":"https:\/\/media.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/Cost-of-Drugs.jpg","width":1511,"height":868},{"@type":"BreadcrumbList","@id":"https:\/\/cms.alj3.clients.lemonhq.io\/es\/perspectives\/healthcare-for-the-many-not-only-the-few-6\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/10.0.2.222\/en\/"},{"@type":"ListItem","position":2,"name":"Atenci\u00f3n sanitaria para muchos, no solo para unos pocos"}]},{"@type":"WebSite","@id":"https:\/\/10.0.2.222\/en\/#website","url":"https:\/\/10.0.2.222\/en\/","name":"Abdul Latif Jameel","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/10.0.2.222\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"}]}},"post-meta-fields":{"_wp_page_template":["default"],"_published_date":["field_6057129b493f5"],"published_date":["20220209"],"_location":["field_601267396ce72"],"location":["Dubai, EAU"],"_featured":["field_601a3b473c5c5"],"featured":["0"],"_footnotes":["field_66fd39afb9383"],"footnotes":[""],"_business_sector":["field_66f6b5bcac8cb"],"business_sector":["Salud"],"_content_series":["field_66fe3c439f8f6"],"content_series":[""],"_old_post_id":["field_66fe3fd59f8f7"],"old_post_id":["95766"],"_short_title":["field_60925d67125ef"],"short_title":["Atenci\u00f3n sanitaria para muchos, no solo para unos pocos"],"_summary":["field_6019304103a20"],"summary":["<p>Entrevista con Melanie Nallicheri, CEO de EQRx, sobre su misi\u00f3n de revolucionar la medicina.<\/p>"],"_mobile_featured_image":["field_66f6b4bee65f3"],"mobile_featured_image":["https:\/\/media.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/Cost-of-Drugs.jpg"],"_push_notification":["field_66f6b47de65f1"],"push_notification":[""],"_publish_mobile":["field_66f6b491e65f2"],"publish_mobile":["0"],"_status":["field_652694983fe12"],"status":["publish"],"_thumbnail_id":["15377"],"_wpml_word_count":["{\"total\":2339,\"to_translate\":{\"ar\":2339,\"zh-hans\":2339,\"fr\":2339,\"ja\":2339,\"es\":2339,\"tr\":2339}}"],"_last_translation_edit_mode":["native-editor"],"amazonS3_cache":["a:12:{s:88:\"\/\/cms.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/Mellanie-Nalicheri-CEO-EQRx.jpg\";a:2:{s:2:\"id\";s:5:\"15378\";s:11:\"source_type\";s:13:\"media-library\";}s:96:\"\/\/cms.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/Mellanie-Nalicheri-CEO-EQRx-221x300.jpg\";a:2:{s:2:\"id\";s:5:\"15378\";s:11:\"source_type\";s:13:\"media-library\";}s:90:\"\/\/media.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/Mellanie-Nalicheri-CEO-EQRx.jpg\";a:2:{s:2:\"id\";s:5:\"15378\";s:11:\"source_type\";s:13:\"media-library\";}s:98:\"\/\/media.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/Mellanie-Nalicheri-CEO-EQRx-221x300.jpg\";a:2:{s:2:\"id\";s:5:\"15378\";s:11:\"source_type\";s:13:\"media-library\";}s:111:\"\/\/cms.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/Dr.-Akram-Bouchenaki-CEO-Abdul-Latif-Jameel-Health.jpg\";a:2:{s:2:\"id\";s:5:\"15379\";s:11:\"source_type\";s:13:\"media-library\";}s:119:\"\/\/cms.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/Dr.-Akram-Bouchenaki-CEO-Abdul-Latif-Jameel-Health-273x300.jpg\";a:2:{s:2:\"id\";s:5:\"15379\";s:11:\"source_type\";s:13:\"media-library\";}s:113:\"\/\/media.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/Dr.-Akram-Bouchenaki-CEO-Abdul-Latif-Jameel-Health.jpg\";a:2:{s:2:\"id\";s:5:\"15379\";s:11:\"source_type\";s:13:\"media-library\";}s:121:\"\/\/media.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/Dr.-Akram-Bouchenaki-CEO-Abdul-Latif-Jameel-Health-273x300.jpg\";a:2:{s:2:\"id\";s:5:\"15379\";s:11:\"source_type\";s:13:\"media-library\";}s:160:\"\/\/cms.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/Alexis-Borisy-Executive-Chairman-Board-of-Directors-Melanie-Nallicheri-Chief-Executive-Officer-EQRx.jpg\";a:2:{s:2:\"id\";s:5:\"15380\";s:11:\"source_type\";s:13:\"media-library\";}s:162:\"\/\/media.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/Alexis-Borisy-Executive-Chairman-Board-of-Directors-Melanie-Nallicheri-Chief-Executive-Officer-EQRx.jpg\";a:2:{s:2:\"id\";s:5:\"15380\";s:11:\"source_type\";s:13:\"media-library\";}s:73:\"\/\/cms.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/ALJ-Health-1.jpg\";a:2:{s:2:\"id\";s:5:\"10723\";s:11:\"source_type\";s:13:\"media-library\";}s:75:\"\/\/media.alj3.clients.lemonhq.io\/wp-content\/uploads\/2024\/10\/ALJ-Health-1.jpg\";a:2:{s:2:\"id\";s:5:\"10723\";s:11:\"source_type\";s:13:\"media-library\";}}"],"_edit_lock":["1778595587:22"],"content":["<h4>Entrevista con Melanie Nallicheri, CEO de EQRx, sobre su misi\u00f3n de revolucionar la medicina.<\/h4>\r\n<p>En junio de 2021 <a href=\"https:\/\/aljhealth.com\/home\">Abdul Latif Jameel Health<\/a> y <a href=\"http:\/\/www.eqrx.com\">EQRx<\/a>, una empresa comprometida con el desarrollo y la entrega de medicamentos innovadores a precios m\u00e1s bajos, firmaron una colaboraci\u00f3n estrat\u00e9gica para la distribuci\u00f3n de dos nuevos f\u00e1rmacos asequibles para el c\u00e1ncer de pulm\u00f3n, una vez que todas las autoridades pertinentes los hayan aprobado, a un potencial de 1500\u00a0millones de personas en todo Oriente Medio, \u00c1frica y Turqu\u00eda.<\/p>\r\n<p>Los dos programas oncol\u00f3gicos, aumolertinib, un inhibidor del receptor del factor de crecimiento epid\u00e9rmico (EGFR), y sugemalimab, un anticuerpo anti-PD-L1, han mostrado datos prometedores en fase III para el tratamiento de pacientes con c\u00e1ncer de pulm\u00f3n no microc\u00edtico (CPNM) avanzado. Ambos tienen el potencial de ofrecer un tratamiento a una fracci\u00f3n del coste de los enfoques existentes.<\/p>\r\n<p>Con esta colaboraci\u00f3n, Abdul Latif Jameel Health comercializar\u00e1 los f\u00e1rmacos en mercados seleccionados de toda la regi\u00f3n de Oriente Medio, as\u00ed como en Turqu\u00eda y toda \u00c1frica, proporcionando acceso a tratamientos asequibles, seguros y efectivos para miles de pacientes con c\u00e1ncer de pulm\u00f3n.<\/p>\r\n<p>Hablamos con <a href=\"https:\/\/www.eqrx.com\/people\/melanie-nallicheri\/\">Melanie Nallicheri<\/a>, CEO de EQRx, y <a href=\"https:\/\/aljhealth.com\/en\/our-people\/akram-bouchenaki\/\">Akram Bouchenaki<\/a>, CEO de Abdul Latif Jameel Health, sobre la asociaci\u00f3n y lo que podr\u00eda significar para los pacientes con c\u00e1ncer en los mercados objetivo.<\/p>\r\n<h2>Melanie, \u00bfpuede hablarnos sobre la misi\u00f3n de EQRx?<\/h2>\r\n\r\n[caption id=\"attachment_95750\" align=\"alignright\" width=\"221\"]<img class=\"size-medium wp-image-95750\" src=\"https:\/\/alj.com\/app\/uploads\/2022\/02\/Mellanie-Nalicheri-CEO-EQRx-221x300.jpg\" alt=\"Mellanie Nalicheri, CEO, EQRx\" width=\"221\" height=\"300\" \/> Melanie Nallicheri<br \/>\r\nCEO de EQRx[\/caption]\r\n\r\n<p><strong>MN: <\/strong>Nuestra misi\u00f3n es mejorar la salud de todos a trav\u00e9s de medicamentos excelentes, innovadores y asequibles,<\/p>\r\n<ul>\r\n\t<li>que personas de todo el mundo puedan acceder a estos medicamentos para tratar enfermedades o afecciones cr\u00f3nicas o potencialmente mortales,<\/li>\r\n\t<li>que los m\u00e9dicos de todo el mundo puedan ofrec\u00e9rselas a sus pacientes sin dificultades administrativas innecesarias y<\/li>\r\n\t<li>que tanto los pagadores como los sistemas sanitarios de todo el mundo puedan poner estos medicamentos a disposici\u00f3n de los pacientes de una manera econ\u00f3micamente sostenible.<\/li>\r\n<\/ul>\r\n<p>B\u00e1sicamente, queremos que los medicamentos innovadores que mejoran nuestras vidas est\u00e9n disponibles y sean accesibles para los pacientes de todo el mundo.<\/p>\r\n<h2>\u00bfPor qu\u00e9 hay tantos problemas de accesibilidad y asequibilidad en la industria farmac\u00e9utica?<\/h2>\r\n<p><strong>MN: <\/strong>En los \u00faltimos a\u00f1os, nuestra comprensi\u00f3n de la medicina, la biolog\u00eda y la ciencia de los datos se ha desarrollado enormemente. Las cosas que podemos hacer hoy en d\u00eda se habr\u00edan visto como ciencia ficci\u00f3n hace una o dos d\u00e9cadas. Normalmente, a medida que la tecnolog\u00eda avanza, los costes, o al menos los precios al consumidor, se reducen. Sin embargo, en la atenci\u00f3n sanitaria, los costes han subido. Esto significa que hemos aumentado nuestra comprensi\u00f3n y nuestras capacidades, pero que la accesibilidad y asequibilidad de estas nuevas soluciones ha disminuido. Nos dimos cuenta de que esta din\u00e1mica no era la correcta y vimos una oportunidad de cambiarla creando un exitoso negocio a escala.<\/p>\r\n\r\n[caption id=\"attachment_95757\" align=\"alignright\" width=\"273\"]<img class=\"size-medium wp-image-95757\" src=\"https:\/\/alj.com\/app\/uploads\/2022\/02\/Dr.-Akram-Bouchenaki-CEO-Abdul-Latif-Jameel-Health-273x300.jpg\" alt=\"Dr. Akram Bouchenaki, CEO, Abdul Latif Jameel Health\" width=\"273\" height=\"300\" \/> Dr. Akram Bouchenaki<br \/>\r\nCEO de Abdul Latif Jameel Health[\/caption]\r\n\r\n<p><strong>AB: <\/strong>Adem\u00e1s de lo que ha dicho Melanie, existe una incre\u00edble necesidad m\u00e9dica insatisfecha de estos f\u00e1rmacos. En la regi\u00f3n del CCG, que generalmente tiene un buen nivel de atenci\u00f3n sanitaria, vemos que el c\u00e1ncer de pulm\u00f3n es el segundo m\u00e1s frecuente entre los hombres y el m\u00e1s mortal. Hasta el 80\u00a0por ciento de los casos se diagnostican en estadios avanzados y la tasa de supervivencia a los cinco a\u00f1os est\u00e1 entre el 10 y el 20 por ciento.<\/p>\r\n<p>Por eso es tan fundamental ampliar en gran medida el acceso a estas terapias. Esa es la visi\u00f3n que estamos intentando hacer realidad.<\/p>\r\n<h2>Este no es un problema nuevo, \u00bfqu\u00e9 tiene de diferente el enfoque de EQRx?<\/h2>\r\n<p><strong>MN: <\/strong>Reconocemos que, para marcar una diferencia real, se necesita una cartera, o cat\u00e1logo, de medicamentos con un tama\u00f1o significativo. Esto nos permite ofrecer muchas opciones para tratar enfermedades cr\u00f3nicas o potencialmente mortales y lograr el mayor impacto. En lugar de empezar con uno o dos f\u00e1rmacos, quisimos empezar con 10, 20 o 30, centr\u00e1ndonos en \u00e1reas cr\u00edticas, como la oncolog\u00eda y las enfermedades inmunitarias-inflamatorias.<\/p>\r\n<p>Tambi\u00e9n estamos abordando el problema desde una perspectiva diferente, bas\u00e1ndonos en un objetivo compartido con los m\u00e9dicos y los pagadores. Normalmente, un fabricante lanza un estupendo f\u00e1rmaco nuevo, pero mantiene un precio elevado para maximizar sus beneficios y mantener felices a sus accionistas. Los m\u00e9dicos quieren ofrecer este f\u00e1rmaco a sus pacientes, mientras que los pagadores, como las aseguradoras o los sistemas sanitarios nacionales, quieren ponerlo a disposici\u00f3n de sus miembros y comunidades. El problema es que el coste es tan alto que solo pueden permitirse recet\u00e1rselo a un determinado n\u00famero de personas, de lo contrario, su presupuesto se arruinar\u00eda. Esto significa que tienen que restringir qui\u00e9n puede beneficiarse de estos f\u00e1rmacos. Es decir, los objetivos de los fabricantes, los m\u00e9dicos\/pagadores y los pacientes est\u00e1n en conflicto entre s\u00ed.<\/p>\r\n<p>Nuestro enfoque es trabajar hacia un <em>objetivo com\u00fan<\/em> para hacer que estos medicamentos est\u00e9n lo m\u00e1s disponibles posible. Para ello, pretendemos conseguir que nuestros precios sean transparentes, sencillos y radicalmente m\u00e1s bajos. Nosotros nos beneficiaremos de vender m\u00e1s de nuestros medicamentos, los m\u00e9dicos y los pagadores se beneficiar\u00e1n al ofrecerles estos tratamientos a m\u00e1s personas sin salirse de sus presupuestos y, por su parte, los pacientes se beneficiar\u00e1n de tener acceso a una atenci\u00f3n sanitaria que mejora sus vidas.<\/p>\r\n<h2>\u00bfQu\u00e9 gran diferencia podr\u00eda suponer esto para los sistemas sanitarios y para los pacientes?<\/h2>\r\n<p><strong>MN: <\/strong>Los beneficios potenciales son enormes. Nuestra misi\u00f3n es ofrecer medicamentos que cambian la vida a precios radicalmente menores, entre un 25 y un 50 por ciento m\u00e1s bajos. Eso marcar\u00eda una diferencia significativa. Por ejemplo, digamos que el gasto global total para un f\u00e1rmaco espec\u00edfico es de 10\u00a0000 millones de USD, algo habitual en muchas enfermedades inmunitarias. Nuestro f\u00e1rmaco podr\u00eda tener un precio de un tercio del precio del f\u00e1rmaco actual, por lo que en un mercado de 10\u00a0000 millones de USD supondr\u00eda inmediatamente un ahorro potencial de m\u00e1s de 6600 millones de USD. Por supuesto, nunca vamos a poseer el 100\u00a0% de un mercado, pero incluso si solo tuvi\u00e9ramos una cuota de mercado del 15\u00a0%, equivalente a 1500 millones de USD, al ofrecer nuestro f\u00e1rmaco a un tercio del precio nosotros ingresar\u00edamos 500\u00a0millones de USD y el sistema sanitario ahorrar\u00eda 1000\u00a0millones de USD. De esta forma, podemos operar un gran negocio y, al mismo tiempo, generar un valor significativo para todas las dem\u00e1s partes interesadas de nuestro ecosistema, sobre todo para los pacientes, que tendr\u00e1n acceso a tratamientos que antes no estaban a su disposici\u00f3n.<\/p>\r\n<h2>\u00bfC\u00f3mo ha podido superar EQRx las barreras que han impedido que alguien hiciera esto antes?<\/h2>\r\n<p><strong>MN: <\/strong>Nuestro modelo de negocio se basa en tres pilares fundamentales que creemos que nos permitir\u00e1n lograr nuestro objetivo. El primero es que, desde el primer d\u00eda, nos hemos centrado en crear una estructura de costes completamente diferente. Somos un nuevo negocio, por lo que hemos podido crear esa estructura desde cero en toda la organizaci\u00f3n.<\/p>\r\n<p>En segundo lugar, estamos creando procesos operativos que aprovechan todo lo que tenemos a nuestra disposici\u00f3n como industria para reducir el coste del desarrollo de las medicinas. Por ejemplo, al utilizar enfoques remotos para monitorizar a los pacientes durante un ensayo cl\u00ednico se pueden realizar ensayos mucho m\u00e1s r\u00e1pido y de forma m\u00e1s eficiente, lo que reduce los costes.<\/p>\r\n<p>Por \u00faltimo, debido a este modelo de negocio \u00fanico, podemos prescindir del enfoque t\u00edpico de venta de f\u00e1rmacos, impulsado por personal de ventas y con un alto nivel de promoci\u00f3n. Nuestros socios deber\u00edan crear el acceso a nuestros medicamentos, en lugar de enviar a cientos de vendedores para que persuadan a la gente para que los compren. Este tipo de modelo impulsado por el mercado no exist\u00eda antes en el sector sanitario global.<\/p>\r\n\r\n[caption id=\"attachment_95729\" align=\"aligncenter\" width=\"2267\"]<img class=\"size-full wp-image-95729\" src=\"https:\/\/alj.com\/app\/uploads\/2022\/02\/Alexis-Borisy-Executive-Chairman-Board-of-Directors-Melanie-Nallicheri-Chief-Executive-Officer-EQRx.jpg\" alt=\"\" width=\"2267\" height=\"1074\" \/> En la imagen (de izq. a dcha.) Alexis Borisy, presidente ejecutivo del Consejo de administraci\u00f3n, y Melanie Nallicheri, CEO de EQRx<br \/>\r\nCr\u00e9dito de la foto \u00a9 Fierce Biotech.[\/caption]\r\n\r\n<h2>Akram, \u00bfqu\u00e9 fue lo que le convenci\u00f3 de que EQRx ser\u00eda un buen socio para Abdul Latif Jameel Health?<\/h2>\r\n<p><strong>AB:<\/strong> Nos interesamos por invertir en EQRx porque estamos muy de acuerdo con su visi\u00f3n, sus valores y su prop\u00f3sito general. El objetivo de Abdul Latif Jameel Health es ser un puente para acelerar el acceso a terapias innovadoras en el sur global. Las dos palabras clave son \u201cacelerar\u201d y \u201cacceso\u201d. Queremos que los medicamentos vitales lleguen m\u00e1s r\u00e1pido y sean accesibles para m\u00e1s personas. La asequibilidad es una parte clave, pero el precio no es el \u00fanico factor que impide que los medicamentos lleguen a quienes los necesitan.<\/p>\r\n<p>En mi carrera profesional he estado en situaciones en las que hemos donado toneladas de f\u00e1rmacos para tratar enfermedades infecciosas a pa\u00edses donde las tasas de prevalencia eran muy altas, pero desafortunadamente los f\u00e1rmacos nunca llegaron a los pacientes que los necesitaban. Por lo tanto, no se trata solo de un problema de asequibilidad.<\/p>\r\n<p>Otra cosa que realmente nos gust\u00f3 del enfoque de EQRx es el modelo de negocio innovador que est\u00e1n construyendo y la forma en que se centran en establecer relaciones con las partes interesadas correctas para el futuro. Es una visi\u00f3n y una estrategia que apoyamos mucho y que esperamos implementar en nuestra parte del mundo.<\/p>\r\n<h2>Melanie, sus dos primeros productos son f\u00e1rmacos contra el c\u00e1ncer: aumolertinib y sugemalimab. \u00bfPor qu\u00e9 decidieron empezar por estos dos?<\/h2>\r\n<p><strong>MN: <\/strong>Cuando empezamos, nos propusimos tener nuestro primer f\u00e1rmaco a disposici\u00f3n de los pacientes en cinco a\u00f1os. Al analizar el mercado en busca de medicamentos para incorporarlos a nuestra cartera tuvimos en mente este objetivo. Tanto aumolertinib como sugemalimab tratan el c\u00e1ncer de pulm\u00f3n no microc\u00edtico, as\u00ed como otros tipos de c\u00e1ncer. Aumolertinib es un tratamiento dirigido en oncolog\u00eda para pacientes con mutaciones impulsadas por el gen EFG, mientras que sugemalimab es una inmunoterapia. En el c\u00e1ncer, esta es la mayor clase de f\u00e1rmaco que conocemos hoy en d\u00eda.<\/p>\r\n<p>Est\u00e1bamos muy entusiasmados con ambos, puesto que demostraron tener una eficacia excelente y un perfil de tolerabilidad s\u00f3lido.<\/p>\r\n<p>Adem\u00e1s, los dos podr\u00edan estar disponibles ya en 2023, mucho antes de nuestro objetivo original de cinco a\u00f1os. Esto nos permite comenzar a tener conversaciones con agencias reguladoras y socios de todo el mundo para iniciar el proceso de llevar estos f\u00e1rmacos a las personas que los necesitan. Es la situaci\u00f3n ideal: un medicamento excepcional, con un gran perfil de tolerabilidad y disponible mucho antes de lo que hab\u00edamos previsto originalmente. Por eso est\u00e1bamos tan entusiasmados con estos dos tratamientos.<\/p>\r\n<h2>Akram, \u00bfc\u00f3mo planea aprovechar la presencia global de Abdul Latif Jameel para llevar estos f\u00e1rmacos a quienes los necesitan?<\/h2>\r\n<p><strong>AB:<\/strong> Este es el tipo de desaf\u00edo para el que se cre\u00f3 Abdul Latif Jameel Health. La visi\u00f3n de <a href=\"https:\/\/alj.com\/en\/our-people\/mohammed-abdul-latif-jameel\/\">Mohammed Jameel<\/a> nos convirti\u00f3 en una parte fundamental de la cadena de innovaci\u00f3n, que va m\u00e1s all\u00e1 de lo que ocurre en el laboratorio. Por supuesto, all\u00ed est\u00e1 el punto de partida, pero la innovaci\u00f3n tambi\u00e9n consiste en encontrar nuevas formas, m\u00e1s r\u00e1pidas y eficaces, de administrar esos tratamientos a los pacientes. Nos vemos a nosotros mismos como los proveedores de esa promesa de innovaci\u00f3n. Estos f\u00e1rmacos van a ser absolutamente fundamentales en la transformaci\u00f3n de la atenci\u00f3n al paciente, en la prolongaci\u00f3n de la vida y en la mejora del tratamiento del c\u00e1ncer. La promesa est\u00e1 ah\u00ed y consideramos que la entrega es como una parte esencial del recorrido de innovaci\u00f3n.<\/p>\r\n<h2>\u00bfCu\u00e1les cree que son los mayores desaf\u00edos a los que se enfrenta EQRx para lograr sus ambiciones?<\/h2>\r\n<p><strong>MN<\/strong>: Nuestro primer reto es desarrollar nuestro cat\u00e1logo de medicamentos y construir nuestra organizaci\u00f3n a escala. Para ello, debemos ser capaz de hacer dos cosas. Uno, necesitamos atraer a algunos de los mejores talentos del sector. En segundo lugar, debemos ser capaces de movilizar un capital significativo para construir r\u00e1pidamente una empresa a escala. Hemos trabajado diligentemente desde el principio. En cuanto a las personas, hemos establecido una marca de talento \u00fanica, tanto por nuestra misi\u00f3n social, que es realmente emocionante para las personas, como por la cultura de EQRx, que recompensa la iniciativa y la innovaci\u00f3n. Animamos y formamos a las personas para que intenten hacer las cosas de forma diferente, incluso aunque algunas ideas no funcionen.<\/p>\r\n<p><strong>AB: <\/strong>Para nosotros, el reto es implementar este modelo innovador y revolucionario. Tenemos que salir y cambiar las percepciones de las personas sobre c\u00f3mo funciona el mercado de los f\u00e1rmacos. No queremos tener ej\u00e9rcitos de representantes de ventas pase\u00e1ndose por los pasillos de los hospitales, lo que supone una enorme p\u00e9rdida de tiempo productivo, sino que nos centramos en el servicio, la educaci\u00f3n y la distribuci\u00f3n. La asociaci\u00f3n con autoridades sanitarias, reguladores y proveedores de atenci\u00f3n m\u00e9dica en general va a ser un factor clave para nuestro \u00e9xito, a medida que construimos un nuevo modelo de medicina en el que los pacientes toman las riendas de su propia salud.<\/p>\r\n<p><img class=\"aligncenter size-full wp-image-95736\" src=\"https:\/\/alj.com\/app\/uploads\/2022\/02\/ALJ-Health.jpg\" alt=\"\" width=\"1516\" height=\"703\" \/><\/p>\r\n<h2>Por \u00faltimo, \u00bfcu\u00e1l es el siguiente paso para ambos?<\/h2>\r\n<p><strong>MN:<\/strong> Nos centraremos en crear nuestro cat\u00e1logo y nuestra organizaci\u00f3n. En este momento tenemos m\u00e1s de 10\u00a0programas en nuestra cartera. De estos, cinco son programas en estadio cl\u00ednico, incluidos aumolertinib y sugemalimab. Tambi\u00e9n tenemos otra opci\u00f3n de inmunoterapia en nuestra cartera, un f\u00e1rmaco para el c\u00e1ncer de mama y otro para las principales enfermedades inmunoinflamatorias, como la artritis reumatoide y la dermatitis at\u00f3pica. Aparte de esto, estamos desarrollando varios programas que a\u00fan est\u00e1n en fases anteriores y se dirigen tanto a enfermedades oncol\u00f3gicas como inmunoinflamatorias. Recientemente tambi\u00e9n hemos anunciado varias colaboraciones de ingenier\u00eda farmacol\u00f3gica con empresas. Para 2025 o 2026 esperamos abordar m\u00e1s del 20\u00a0% del gasto del mercado mundial de f\u00e1rmacos de marca, que asciende a un bill\u00f3n de d\u00f3lares. Sin duda, se trata de un prop\u00f3sito muy emocionante.<\/p>\r\n<p><strong>AB:<\/strong> Estamos ansiosos por formar parte de ese viaje. Tenemos muchas ganas de trabajar con Melanie y el equipo de EQRx para poner en pr\u00e1ctica nuestra estrategia. Ah\u00ed es cuando empieza realmente el trabajo. Estamos entusiasmados. Nos encantar\u00eda que los pacientes accedieran a estos nuevos y emocionantes f\u00e1rmacos tan pronto como sea posible, as\u00ed que haremos todo lo que est\u00e9 en nuestra mano para lograrlo en los pr\u00f3ximos a\u00f1os y, con suerte, m\u00e1s all\u00e1.<\/p>"],"_content":[""],"_ame_cpe_post_policy":["{\"accessProtection\":{\"active\":\"replace\"}}"],"_edit_last":["22"],"_wpml_media_duplicate":["1"],"_wpml_media_featured":["1"],"_yoast_wpseo_content_score":["60"],"_yoast_wpseo_estimated-reading-time-minutes":["11"]},"_links":{"self":[{"href":"https:\/\/cms.alj3.clients.lemonhq.io\/es\/wp-json\/wp\/v2\/perspectives\/15389","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cms.alj3.clients.lemonhq.io\/es\/wp-json\/wp\/v2\/perspectives"}],"about":[{"href":"https:\/\/cms.alj3.clients.lemonhq.io\/es\/wp-json\/wp\/v2\/types\/perspectives"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cms.alj3.clients.lemonhq.io\/es\/wp-json\/wp\/v2\/media\/15377"}],"wp:attachment":[{"href":"https:\/\/cms.alj3.clients.lemonhq.io\/es\/wp-json\/wp\/v2\/media?parent=15389"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}